Filing Details
- Accession Number:
- 0001140361-18-000914
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-04 19:26:13
- Reporting Period:
- 2018-01-02
- Accepted Time:
- 2018-01-04 19:26:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197355 | J Henry Fuchs | C/O Biomarin Pharmaceutical Inc. 770 Lindaro St. San Rafael CA 94901 | President, Worldwide R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-01-02 | 5,000 | $26.49 | 138,976 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2018-01-02 | 10,000 | $37.46 | 148,976 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-01-02 | 15,000 | $89.23 | 133,976 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy Common Stock) | Disposition | 2018-01-02 | 5,000 | $0.00 | 5,000 | $26.49 |
| Common Stock | Stock Option (right to buy Common Stock) | Disposition | 2018-01-02 | 10,000 | $0.00 | 10,000 | $37.46 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,225 | 2011-11-12 | 2021-05-11 | No | 4 | M | Direct |
| 27,331 | 2012-11-08 | 2022-05-07 | No | 4 | M | Direct |
Footnotes
- Trade made pursuant to a 10b5-1 plan executed on May 9, 2017.
- Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) exclude 1,435 shares as previously reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 1,011 shares inadvertently included in prior reports based on a reconciliation with the Company's records.
- The price in column 4 is the weighted average price. The price actually received ranged from $88.84 to $90.00. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- Reflects the number of options outstanding after the transactions from this specific stock option grant.
Billionaire Hedge Funds
